{"id":616,"date":"2024-09-11T13:57:45","date_gmt":"2024-09-11T13:57:45","guid":{"rendered":"https:\/\/www.ull.es\/institutos\/instituto-tecnologias-biomedicas\/?page_id=616"},"modified":"2024-09-11T13:57:45","modified_gmt":"2024-09-11T13:57:45","slug":"personalizacion-de-tratamientos-oncologicos","status":"publish","type":"page","link":"https:\/\/www.ull.es\/institutos\/instituto-tecnologias-biomedicas\/personalizacion-de-tratamientos-oncologicos\/","title":{"rendered":"Personalizaci\u00f3n de tratamientos oncol\u00f3gicos"},"content":{"rendered":"

Personalizaci\u00f3n de tratamientos oncol\u00f3gicos<\/h1>\n

Investigador responsable<\/b><\/h4>\n\n\n\n
<\/td>\nFernando Guti\u00e9rrez Nicol\u00e1s, PhD<\/strong><\/p>\n

Jefe Unidad de Investigaci\u00f3n, Facultativo Especialista de \u00c1rea Farmacia Hospitalaria CHUC<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Investigadores colaboradores<\/b><\/p>\n

    \n
  • Ruth Ramos D\u00edaz, PhD (Bi\u00f3loga Molecular, Responsable de la Secci\u00f3n de Gen\u00e9tica, Unidad de Investigaci\u00f3n, CHUC)<\/span><\/li>\n
  • Mar\u00eda Micaela Vi\u00f1a, PhD (Farmac\u00e9utica Hospitalaria \u00e1rea Onco-Hematolog\u00eda, Responsable de la Secci\u00f3n de Hematolog\u00eda, Unidad de Investigaci\u00f3n, CHUNSC)<\/span><\/li>\n
  • Sara Garc\u00eda, PhD (Farmac\u00e9utica Hospitalaria \u00e1rea Onco-Hematolog\u00eda, Responsable de la Secci\u00f3n de Inmunomediadas y del Desarrollo Estad\u00edstico, CHUC)<\/span><\/li>\n
  • Ivette Mourani (Bi\u00f3loga Molecular, Responsable del \u00c1rea de Cromatograf\u00eda y Data-manager)<\/span><\/li>\n
  • Juana Oramas, PhD (Jefa del Servicio de Oncolog\u00eda M\u00e9dica, CHUC – Apoyo al \u00c1rea de Oncolog\u00eda)<\/span><\/li>\n
  • Mat\u00edas Llabr\u00e9s, PhD (Catedr\u00e1tico de Tecnolog\u00eda Farmac\u00e9utica, ULL \u2013 desarrollo de modelos cl\u00ednicos)<\/span><\/li>\n<\/ul>\n

    Estudiantes de doctorado e investigadores en formaci\u00f3n<\/b><\/p>\n

      \n
    • Betel del Rosario, PhD (Programa de Doctorado Ciencias de la Salud, ULL. Farmac\u00e9utica Hospitalaria \u00e1rea Inmunomediadas, Responsable de la Secci\u00f3n de Oncolog\u00eda, CHUC)<\/span><\/li>\n<\/ul>\n

      L\u00edneas de investigaci\u00f3n<\/b><\/p>\n

        \n
      1. Mutaciones germinales en la individualizaci\u00f3n de los tratamientos<\/b>. Identificar alteraciones gen\u00e9ticas que condicionan, principalmente, la seguridad de los tratamientos y su eficacia.<\/span><\/li>\n
      2. Mutaciones som\u00e1ticas en la individualizaci\u00f3n de los tratamientos oncol\u00f3gicos<\/b>. Identificar de alteraciones gen\u00e9ticas que condicionan, la eficacia de los tratamientos.<\/span><\/li>\n
      3. Monitorizaci\u00f3n de niveles plasm\u00e1ticos de f\u00e1rmacos<\/b>. Poner de manifiesto el valor cl\u00ednico de que poseen los intervalos terap\u00e9uticos de los f\u00e1rmacos estableciendo su relaci\u00f3n con la eficacia y seguridad de los mismos.\u00a0<\/span><\/li>\n
      4. Adherencia a los tratamientos<\/b>. Estudiar las consecuencias cl\u00ednicas de una falta de adherencia al tratamiento farmacol\u00f3gico y analizar los condicionantes de la misma.<\/span><\/li>\n<\/ol>\n

        Proyectos financiados<\/b><\/p>\n

          \n
        • Huella gen\u00e9tica e individualizaci\u00f3n del tratamiento en el paciente pedi\u00e1trico onco\u2010 hematol\u00f3gico (PIFIISC22\/39). IP: Fernando Guti\u00e9rrez Nicol\u00e1s. Fundaci\u00f3n Canaria Instituto de Investigaci\u00f3n Sanitaria de Canarias, FIISC (2023-2024, 18.301,84 \u20ac)<\/span><\/li>\n
        • Relevancia cl\u00ednica del gen UGT1A en el tratamiento con Sacituzumab-Govitecan para el c\u00e1ncer de mama triple negativo metast\u00e1sico. IP: Fernando Guti\u00e9rrez Nicol\u00e1s. Fundaci\u00f3n Canaria Instituto de Investigaci\u00f3n Sanitaria de Canarias, FIISC (2023-2025, 18.000 \u20ac)<\/span><\/li>\n
        • Farmacocin\u00e9tica del natalizumab en el tratamiento de la EM. IP: Fernando Guti\u00e9rrez Nicol\u00e1s. Fundaci\u00f3n Canaria Instituto de Investigaci\u00f3n Sanitaria de Canarias, FIISC (2023-2025, 8.000 \u20ac)<\/span><\/li>\n<\/ul>\n

          Publicaciones 2023<\/b><\/p>\n

            \n
          • Cantarelli L, Pestana Grafi\u00f1a D, Gonzalez Perez A, Garc\u00eda Gil S, <\/span>Guti\u00e9rrez Nicol\u00e1s F<\/b>, Ramos Santana E, Navarro D\u00e1vila MA, Otazo P\u00e9rez SM, Calzado G\u00f3mez G, Perez Reyes S, Nazco Casariego GJ. Efficacy and Safety of Erenumab, Galcanezumab, and Fremanezumab in the Treatment of Drug-Resistant Chronic Migraine: Experience in Real Clinical Practice. <\/span>Ann Pharmacother<\/span><\/i>. 2023 Apr;57(4):416-424. DOI: 10.1177\/10600280221118402<\/span><\/li>\n
          • Del Rosario Garc\u00eda B, Vi\u00f1a Romero MM, Gonz\u00e1lez Rosa V, Alarc\u00f3n Payer C, Oliva Oliva L, Merino Alonso FJ, Nazco Casariego GJ, <\/span>Guti\u00e9rrez Nicol\u00e1s F<\/b>. Incorporaci\u00f3n al ITB, Dr. Guti\u00e9rrez F. UI-CHUC Risk factors determining adherence to tyrosine kinase inhibitors in chronic myeloid leukaemia. <\/span>J Oncol Pharm Pract<\/span><\/i>. 2023 Sep 25:10781552231196130. DOI: 10.1177\/10781552231196130. Epub ahead of print<\/span><\/li>\n
          • Miarons M, Manzaneque Gord\u00f3n A, Riera P, <\/span>Guti\u00e9rrez Nicol\u00e1s F<\/b>; RedDPYD Research Group with the Spanish Society of Hospital Pharmacy (SEFH). Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study. <\/span>Oncologist<\/span><\/i>. 2023 May;28(5):e304-e308. DOI: 10.1093\/oncolo\/oyad077<\/span><\/li>\n
          • Morales-Arr\u00e1ez D, Ben\u00edtez-Zafra F, D\u00edaz-Flores F, Medina-Alonso MJ, Santiago LG, P\u00e9rez-P\u00e9rez V, <\/span>Guti\u00e9rrez-Nicol\u00e1s F, Hern\u00e1ndez-Guerra M<\/b>. A slowdown of hepatitis C diagnosis in high-prevalence groups and with decentralized diagnostic strategies during the COVID-19 pandemic. <\/span>Revista Espa\u00f1ola de Enfermedades Digestivas<\/span><\/i>. 2023 Apr;115(4):175-180. DOI: 10.17235\/reed.2022.8412\/2021<\/span><\/li>\n<\/ul>\n

            Otras publicaciones representativas de los \u00faltimos a\u00f1os<\/b><\/p>\n

              \n
            • Cantarelli L, Carrillo Palau M, <\/span>Hernandez Guerra M<\/b>, Nazco Casariego GJ, <\/span>Gutierrez Nicol\u00e1s F<\/b>. Definition of a therapeutic range for predicting long-term infliximab response in patients with inflammatory bowel disease. <\/span>Med Clin (Barc)<\/span><\/i>. 2023 Feb 10;160(3):107-112. DOI: 10.1016\/j.medcli.2022.05.008<\/span><\/li>\n
            • Del Rosario Garc\u00eda B, Gonz\u00e1lez Garc\u00eda I, Vi\u00f1a Romero MM, Gonz\u00e1lez Garc\u00eda J, Ramos D\u00edaz R, Mourani Padr\u00f3n I, Lakhwani Lakhwani S, Nazco Casariego GJ, <\/span>Guti\u00e9rrez Nicol\u00e1s F<\/b>. Imatinib plasma levels in patients with chronic myeloid leukaemia under routine clinical practice conditions. <\/span>J Oncol Pharm Pract<\/span><\/i>. 2021 Oct 18:10781552211052535. DOI: 10.1177\/10781552211052535<\/span><\/li>\n
            • Vi\u00f1a-Romero MM, Ramos-Diaz R, Mourani-Padron I, Gonzalez-Mendez H, Gonzalez-Cruz M, Nazco-Casariego GJ, Merino-Alonso JF, Diaz-Vera J, <\/span>Guti\u00e9rrez-Nicol\u00e1s F<\/b>. Extended Stability of Reconstituted Lyophilized Erwinia L-asparaginase in Vials. <\/span>In Vivo<\/span><\/i>. 2020;34(5):2419-2421. DOI: 10.21873\/invivo.12055<\/span><\/li>\n
            • Vi\u00f1a-Romero MM, Ramos D\u00edaz R, Gonz\u00e1lez Garc\u00eda J, Nazco-Casariego G, D\u00edaz-Vera J, <\/span>Guti\u00e9rrez-Nicol\u00e1s F<\/b>. Extended enzymatic stability of reconstituted lyophilized PEG-asparaginase in vials. <\/span>J Oncol Pharm Pract<\/span><\/i>. 2021 Jul;27(5):1102-1105. DOI:10.1177\/1078155220950001<\/span><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"

              Personalizaci\u00f3n de tratamientos oncol\u00f3gicos Investigador responsable Fernando Guti\u00e9rrez Nicol\u00e1s, PhD Jefe Unidad de Investigaci\u00f3n, Facultativo Especialista de \u00c1rea Farmacia Hospitalaria CHUC   Investigadores colaboradores Ruth Ramos D\u00edaz, PhD (Bi\u00f3loga Molecular, Responsable de la Secci\u00f3n de Gen\u00e9tica, Unidad de Investigaci\u00f3n, CHUC) Mar\u00eda Micaela Vi\u00f1a, PhD (Farmac\u00e9utica Hospitalaria \u00e1rea Onco-Hematolog\u00eda, Responsable de la Secci\u00f3n de Hematolog\u00eda, Unidad…<\/p>\n","protected":false},"author":6,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/www.ull.es\/institutos\/instituto-tecnologias-biomedicas\/wp-json\/wp\/v2\/pages\/616"}],"collection":[{"href":"https:\/\/www.ull.es\/institutos\/instituto-tecnologias-biomedicas\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ull.es\/institutos\/instituto-tecnologias-biomedicas\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ull.es\/institutos\/instituto-tecnologias-biomedicas\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ull.es\/institutos\/instituto-tecnologias-biomedicas\/wp-json\/wp\/v2\/comments?post=616"}],"version-history":[{"count":1,"href":"https:\/\/www.ull.es\/institutos\/instituto-tecnologias-biomedicas\/wp-json\/wp\/v2\/pages\/616\/revisions"}],"predecessor-version":[{"id":617,"href":"https:\/\/www.ull.es\/institutos\/instituto-tecnologias-biomedicas\/wp-json\/wp\/v2\/pages\/616\/revisions\/617"}],"wp:attachment":[{"href":"https:\/\/www.ull.es\/institutos\/instituto-tecnologias-biomedicas\/wp-json\/wp\/v2\/media?parent=616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}